Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12 F36V mutant) (FKBP12 F36V)

Target
FKBP12 F36V
Molecular classification
Enzyme, Receptor, Other
01

Overview

FKBP12 F36V is an engineered variant of the human Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12), where the phenylalanine at position 36 is replaced by a valine residue (Clackson et al., 1998). This specific mutation creates a unique hydrophobic pocket, or "hole," in the protein's binding site that accommodates "bumped" synthetic ligands with high specificity (Nabet et al., 2018). These ligands, such as AP1867 or Shield-1, are designed to bind the mutant protein with high affinity while exhibiting minimal interaction with the wild-type FKBP12 (Banaszynski et al., 2006). This "bump-and-hole" strategy is the foundation of the Degradation TAG (dTAG) system, which enables the rapid and reversible degradation of any protein fused to the FKBP12 F36V tag (Nabet et al., 2018). In this system, a heterobifunctional molecule like dTAG-13 recruits an E3 ubiquitin ligase to the fusion protein, leading to its ubiquitination and proteasomal destruction (Addgene, 2018). Beyond degradation, the mutant is used in "destabilizing domain" (DD) systems to control protein stability and in "suicide switches" for cell therapies (Straathof et al., 2005). For example, the dimerizing drug rimiducid (AP1903) can be used to induce apoptosis in CAR-T cells expressing a caspase-9-FKBP12 F36V fusion (Straathof et al., 2005). Consequently, FKBP12 F36V serves as a critical tool for target validation in drug discovery and a safety mechanism in advanced biologics (Chemical Probes Portal, 2021). The system's ability to provide precise temporal control over protein levels makes it invaluable for studying complex biological pathways. Overall, FKBP12 F36V is a versatile engineered target that bridges chemical biology and therapeutic development.

Other names
FKBP12 F36VFKBP12(F36V)FKBPVF36V-FKBPFKBP1A F36VdTAGFK506-binding protein 12 (F36V mutant)
02

Mechanism of action

Induced proximity, targeted protein degradation, protein stabilization, and dimerization.

03

Biological functions

Protein foldingCell deathOther
04

Disease associations

CancerOther
05

Safety considerations

Hook effectPotential off-target binding to wild-type FKBP12Immunogenicity of the mutant tag
06

Interacting drugs

dTAG-13

8 more in the full profile.

07

Biomarkers

Fusion protein levelsmCherry fluorescenceLuciferase activity

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12 F36V mutant) (FKBP12 F36V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12 F36V mutant) (FKBP12 F36V).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call